Pharmacogenomic tests in Oncology - finding the right dose
A pharmacogenetics/genomics (PGx) anticancer drug testing program is being developed by Kurtz and his group at the Brazilian National Cancer Institute (INCA). Drug -gene pairs were selected for PGx testing based on the presence of clinically validated PGx associations and the availability of interna...
Saved in:
| Main Authors: | Jeziel Basso, Gilberto Schwartsmann |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações Ltda.
2021-10-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | http://www.brazilianjournalofoncology.com.br/details/153/en-US/pharmacogenomic-tests-in-oncology---finding-the-right-dose |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)
by: Guilherme Suarez-Kurtz
Published: (2021-10-01) -
Thiopurine S-methyl Transferase (TPMT) Enzyme Level in Healthy Sudanese Population
by: Rayan Khalid, et al.
Published: (2024-09-01) -
Study of polymorphisms of UGT1A1 and DPYD genes in chemotherapy for colorectal cancer
by: N. N. Timoshkina, et al.
Published: (2019-01-01) -
Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on <i>UGT1A1</i> Genotypes: A Systematic Review
by: Xando Díaz-Villamarín, et al.
Published: (2025-04-01) -
Balance of care activity after EMA recommendation for DPYD gene testing in Galicia
by: Almudena Gil-Rodríguez, et al.
Published: (2025-03-01)